================================================================================

                                  UNITED STATES
                       SECURITIES AND EXCHANGE COMMISSION
                             WASHINGTON, D.C. 20549


                                    FORM 10-Q

              [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d)
                     OF THE SECURITIES EXCHANGE ACT OF 1934

                  For the quarterly period ended June 30, 2000

                                       OR

             [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (d)
                     OF THE SECURITIES EXCHANGE ACT OF 1934

                        For the transition period from to

                           Commission File No. 0-20260
                           Commission File No. 1-11440

                            INTEGRAMED AMERICA, INC.
             (Exact name of Registrant as specified in its charter)


                Delaware                                  06-1150326
    (State or other jurisdiction            (I.R.S. employer identification no.)
   of incorporation or organization)

        One Manhattanville Road
          Purchase, New York                                 10577
(Address of principal executive offices)                  (Zip code)


                                 (914) 253-8000
              (Registrant's telephone number, including area code)

         Indicate by check mark whether the Registrant (1) has filed all reports
required to be filed by Section 13 or 15(d) of the  Securities  Exchange  Act of
1934  during  the  preceding  12 months  (or for such  shorter  period  that the
Registrant was required to file such reports),  and (2) has been subject to such
filing requirements for the past 90 days.

                                Yes [X]    No [ ]

         The aggregate number of shares of the Registrant's  Common Stock,  $.01
par value, outstanding on August 1, 2000 was 4,057,347.

================================================================================

<PAGE>


                            INTEGRAMED AMERICA, INC.
                                    FORM 10-Q

                                TABLE OF CONTENTS


                                                                            PAGE

PART I  -   FINANCIAL INFORMATION

    Item 1. Financial Statements

               Consolidated Balance Sheets at June 30, 2000 (unaudited) and
                  December 31, 1999........................................... 3

               Consolidated Statements of Operations for the three and
                  six-month periods ended June 30, 2000 and 1999 (unaudited).. 4

               Consolidated Statements of Cash Flows for the six-month periods
                  ended June 30, 2000 and 1999 (unaudited).................... 5

               Notes to Consolidated Financial Statements (unaudited)....... 6-7

    Item 2. Management's Discussion and Analysis of Financial Condition and
            Results of Operations.......................................... 8-11

    Item 3. Quantitative and Qualitative Disclosures About Market Risk........11


PART II -   OTHER INFORMATION

    Item 1. Legal Proceedings.................................................12

    Item 2. Changes in Securities.............................................12

    Item 3. Defaults upon Senior Securities...................................12

    Item 4. Submission of Matters to a Vote of Security Holders...............12

    Item 5. Other Information.................................................12

    Item 6. Exhibits and Reports on Form 8-K..................................12


SIGNATURES              ......................................................13

INDEX TO EXHIBITS       ......................................................14

                                       2

<PAGE>


PART I -- FINANCIAL INFORMATION

    Item 1.      Consolidated Financial Statements

<TABLE>
                            INTEGRAMED AMERICA, INC.
                           CONSOLIDATED BALANCE SHEETS
              (all dollars in thousands, except per share amounts)
                                     ASSETS
<CAPTION>
                                                                                                June 30,     December 31,
                                                                                                ----------   ------------
                                                                                                   2000          1999
                                                                                                ----------   ------------
                                                                                                (unaudited)
Current assets:
<S>                                                                                                <C>          <C>
  Cash and cash equivalents ....................................................................   $ 3,532      $ 3,650
  Patient accounts receivable, less allowance for doubtful accounts of $881 and $851
    in 2000 and 1999, respectively..............................................................     9,430       10,460
  Business Service fees receivable, less allowance for doubtful accounts of $150 and $0
    in 2000 and 1999, respectively..............................................................       375          890
  Other current assets .........................................................................     1,184        1,162
                                                                                                   -------      -------
      Total current assets......................................................................    14,521       16,162
  Fixed assets, net ............................................................................     5,354        5,965
  Intangible assets, net........................................................................    18,206       18,163
  Other assets..................................................................................       493          525
                                                                                                   -------      -------
      Total assets..............................................................................   $38,574      $40,815
                                                                                                   =======      =======

                      LIABILITIES AND SHAREHOLDERS' EQUITY
Current liabilities:
  Accounts payable..............................................................................   $ 1,763      $ 1,080
  Accrued liabilities...........................................................................     2,694        2,948
  Due to Medical Practices......................................................................     1,731        1,768
  Current portion of long-term notes payable and other obligations..............................     1,131        1,691
  Patient deposits..............................................................................     2,692        2,970
                                                                                                   -------      -------
      Total current liabilities.................................................................    10,011       10,457
                                                                                                   -------      -------
Long-term notes payable and other obligations...................................................     3,153        3,719
                                                                                                   -------      -------
Shareholders' equity:
  Preferred  Stock,  $1.00 par value - 3,165,644  shares  authorized in 2000 and
    1999,  2,500,000  undesignated;   665,644  shares  designated  as  Series  A
    Cumulative  Convertible of which 165,644 shares were issued and  outstanding
    in 2000 and
    1999, respectively..........................................................................       166          166
  Common Stock, $.01 par value -  50,000,000 shares authorized in 2000 and 1999;
    and 5,368,960  shares issued in 2000 and 1999...............................................        54           54
  Capital in excess of par .....................................................................    54,074       54,140
  Accumulated deficit ..........................................................................   (24,572)     (25,230)
  Treasury Stock, at cost - 1,311,613 and 746,863 shares in 2000 and 1999, respectively.........    (4,312)      (2,491)
                                                                                                   -------      -------
      Total shareholders' equity ...............................................................    25,410       26,639
                                                                                                   -------      -------
      Total liabilities and shareholders' equity................................................   $38,574      $40,815
                                                                                                   =======      =======
</TABLE>

        See accompanying notes to the consolidated financial statements.

                                      3

<PAGE>

<TABLE>

                            INTEGRAMED AMERICA, INC.
                      CONSOLIDATED STATEMENTS OF OPERATIONS
              (all amounts in thousands, except per share amounts)


<CAPTION>
                                                                            For the                    For the
                                                                       three-month period         six-month period
                                                                         ended June 30,             ended June 30,
                                                                       ------------------         ------------------
                                                                        2000        1999           2000        1999
                                                                       ------      ------         ------      ------
                                                                           (unaudited)                (unaudited)

<S>                                                                   <C>          <C>            <C>         <C>
Revenues, net ...................................................     $13,527      $10,860        $27,135     $21,392

Cost of services incurred:
   Employee compensation and related expenses....................       5,370        4,195         10,467       8,262
   Direct materials..............................................       2,680        1,211          5,161       2,306
   Occupancy costs...............................................         847          687          1,660       1,362
   Depreciation..................................................         345          300            679         609
   Other expenses................................................       2,206        1,969          5,119       4,021
                                                                      -------      -------        -------     -------
     Total cost of services rendered.............................      11,448        8,362         23,086      16,560
                                                                      -------      -------        -------     -------

Contribution.....................................................       2,079        2,498          4,049       4,832

General and administrative expenses..............................       1,390        1,513          2,739       2,893
Amortization of intangible assets................................         214          261            434         505
Interest income..................................................         (35)         (18)           (85)        (41)
Interest expense.................................................         103          125            219         260
                                                                      -------      -------        -------     -------
   Total other expenses..........................................       1,672        1,881          3,307       3,617
                                                                      -------      -------       --------     -------

Income before income taxes.......................................         407          617            742       1,215
Provision for income taxes.......................................          39           91             84         171
                                                                      -------      -------        -------     -------

Net income.......................................................     $   368      $   526        $   658     $ 1,044
Less: Dividends paid and/or accrued on Preferred Stock...........          33           33             66          66
                                                                      -------      -------        -------     -------
Net income applicable to Common Stock............................     $   335      $   493        $   592     $   978
                                                                      =======      =======        =======     =======

Basic and diluted earnings per share of Common Stock.............     $  0.08      $  0.10        $  0.14     $  0.20
                                                                      =======      =======        =======     =======

Weighted average shares - basic..................................       4,163        4,887          4,270       4,931
                                                                      =======      =======        =======     =======
Weighted average shares - diluted................................       4,226        4,962          4,334       5,008
                                                                      =======      =======        =======     =======

</TABLE>


        See accompanying notes to the consolidated financial statements.

                                       4
<PAGE>

<TABLE>


                            INTEGRAMED AMERICA, INC.
                      CONSOLIDATED STATEMENTS OF CASH FLOWS
                           (all amounts in thousands)

  <CAPTION>
                                                                                            For the
                                                                                       six-month period
                                                                                        ended June 30,
                                                                                       -----------------
                                                                                        2000       1999
                                                                                       ------     ------
                                                                                          (unaudited)
Cash flows from operating activities:
<S>                                                                                  <C>        <C>
   Net income ......................................................................  $  658      $1,044
   Adjustments to reconcile net income to net cash provided by operating activities:
      Depreciation and amortization.................................................   1,349       1,264
Change in assets and liabilities--
     Decrease (increase) in assets:
        Patient accounts receivable.................................................   1,030       1,063
        Business Services fees receivable...........................................     515        (208)
        Other current assets........................................................     (22)        533
        Other assets................................................................      32          97
     Increase (decrease) in liabilities:
         Accounts payable...........................................................     683         170
         Accrued liabilities........................................................      19         540
         Due to Medical Practices...................................................     (37)       (692)
         Patient deposits...........................................................    (278)       (877)
                                                                                      ------      ------
Net cash provided by operating activities...........................................   3,949       2,934
                                                                                      ------      ------

Cash flows used in investing activities:
     Purchase of fixed assets and leasehold improvements............................    (588)     (1,443)
     Proceeds from sale of fixed assets and leasehold improvements..................      10          --
     Payment for exclusive Business Service rights..................................    (476)         --
                                                                                      ------      ------
Net cash used in investing activities...............................................  (1,054)     (1,443)
                                                                                      ------      ------

Cash flows used in financing activities:
     Proceeds from IVP Care, Inc....................................................      --         150
     Principal repayments on debt...................................................  (1,060)     (1,540)
     Principal repayments under capital lease obligations...........................     (66)        (22)
     Repurchase of Common Stock.....................................................  (1,821)       (713)
     Dividends paid on Convertible Preferred Stock..................................     (66)        (66)
                                                                                      ------      ------
Net cash used in financing activities...............................................  (3,013)     (2,191)
                                                                                      ------      ------

Net decrease in cash................................................................    (118)       (700)
Cash at beginning of period.........................................................   3,650       4,241
                                                                                      ------      ------
Cash at end of period...............................................................  $3,532      $3,541
                                                                                      ======      ======
</TABLE>


        See accompanying notes to the consolidated financial statements.

                                       5
<PAGE>


                            INTEGRAMED AMERICA, INC.
                   NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
                                   (unaudited)


NOTE 1 -- INTERIM RESULTS:

     The  accompanying  unaudited  consolidated  financial  statements have been
prepared in accordance with the instructions to Form 10-Q and,  accordingly,  do
not include all of the information and footnotes  required by generally accepted
accounting  principles  for  complete  financial  statements.  In the opinion of
management,  the accompanying unaudited interim financial statements contain all
adjustments  (consisting only of normal recurring accruals) necessary to present
fairly the  financial  position at June 30, 2000,  and the results of operations
and cash flows for the  interim  period  presented.  Operating  results  for the
interim  period are not  necessarily  indicative of results that may be expected
for the year ending December 31, 2000. These financial statements should be read
in conjunction  with the financial  statements and notes thereto included in the
Company's Annual Report on Form 10-K for the year ended December 31, 1999.

     Certain  prior year  amounts  have been  reclassified  to conform  with the
current year presentation.

NOTE 2 -- EARNINGS PER SHARE:

     The  reconciliation  of the  numerators and  denominators  of the basic and
diluted EPS  computations  for the three-month and six-month  periods ended June
30, 2000 and 1999 is as follows (000's omitted, except for per share amounts):

<TABLE>
<CAPTION>
                                                                     For the                 For the
                                                                   three-month              six-month
                                                                  period ended             period ended
                                                                    June 30,                 June 30,
                                                                  ------------             ------------
                                                                  2000    1999             2000    1999
                                                                  ----    ----             ----    ----
                                                                   (unaudited)              (unaudited)

Numerator
<S>                                                             <C>     <C>              <C>     <C>
Net Income ...................................................   $ 368   $ 526            $ 658   $1,044
Less: Preferred Stock dividends paid..........................      33      33               66       66
                                                                 -----   -----            -----   ------
Net income available to common stockholders...................   $ 335   $ 493            $ 592   $  978
                                                                 =====   =====            =====   ======

Denominator
Weighted average shares basic.................................   4,163   4,887            4,270    4,931
Effect of dilutive options and warrants.......................      63      75               64       77
                                                                 -----   -----            -----   ------
Weighted average shares and dilutive potential
    common shares.............................................   4,226   4,962            4,334    5,008
                                                                 =====   =====            =====   ======

Basic and diluted EPS.........................................   $0.08   $0.10            $0.14   $ 0.20
</TABLE>

    For both the three and six-month  periods ended June 30, 2000, the effect of
the  assumed  exercise of options to purchase  approximately  550,000  shares of
Common  Stock at  exercise  prices  ranging  from  $3.19 to $5.00 per share were
excluded in computing the diluted per share amount  because the exercise  prices
of the  options  were  greater  than the average  market  price of the shares of
Common Stock, therefore, causing these options to be antidilutive.  For both the
three and  six-month  periods  ended June 30,  2000,  the effect of the  assumed
exercise of warrants to purchase approximately 103,000 shares of Common Stock at
exercise prices ranging from $4.12 to $8.54 per share were excluded in computing
the diluted per share amount  because the exercise  prices of the warrants  were
greater than the average market price of the shares of Common Stock,  therefore,
causing these warrants to be antidilutive.

                                       6

<PAGE>
                            INTEGRAMED AMERICA, INC.
                   NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
                                   (unaudited)


    For both the three and six-month  periods ended June 30, 1999, the effect of
the assumed  exercise of options to  purchase  approximately  338,000 and 47,000
shares of Common Stock,  respectively,  at exercise prices ranging from $4.00 to
$5.00  and from  $4.63 to  $5.00,  respectively,  per  share  were  excluded  in
computing  the  diluted per share  amount  because  the  exercise  prices of the
options  where  greater  than the average  market  price of the shares of Common
Stock, therefore,  causing these options to be antidilutive.  For both the three
and six-month periods ended June 30, 1999, the effect of the assumed exercise of
warrants to purchase  approximately  121,000 and 75,000  shares of Common Stock,
respectively,  at exercise  prices ranging from $4.12 to $8.54 and from $4.94 to
$8.54, respectively,  per share were excluded in computing the diluted per share
amount because the exercise prices of the warrants were greater than the average
market price of the shares of Common Stock, therefore, causing these warrants to
be antidilutive.

                                       7
<PAGE>




Item 2.  Management's Discussion and Analysis of Financial Condition and Results
         of Operations

     The following  discussion and analysis  should be read in conjunction  with
the  consolidated  financial  statements  and  notes  thereto  included  in this
quarterly  report and with the Company's Annual Report on Form 10-K for the year
ended December 31, 1999.

Results of Operations

     The following table shows the percentage of revenues represented by various
expense  and  other  income  items  reflected  in  the  Company's   Consolidated
Statements of Operations.

<TABLE>
<CAPTION>
                                                                          For the                For the
                                                                     three-month period      six-month period
                                                                       ended June 30,          ended June 30,
                                                                     ------------------      -----------------
                                                                       2000       1999        2000       1999
                                                                     -------     ------      ------     ------
                                                                         (unaudited)            (unaudited)

        <S>                                                          <C>        <C>         <C>        <C>
         Revenues, net......................................          100.0%     100.0%      100.0%     100.0%
         Costs of services incurred:
              Employee compensation and related expenses....           39.7       38.6        38.6       38.6
              Direct materials..............................           19.8       11.1        19.0       10.8
              Occupancy costs...............................            6.3        6.3         6.1        6.4
              Depreciation..................................            2.5        2.8         2.5        2.8
              Other expenses................................           16.3       18.2        18.9       18.8
                                                                      -----      -----       -----      -----
              Total costs of services.......................           84.6       77.0        85.1       77.4
         Contribution.......................................           15.4       23.0        14.9       22.6
                                                                      -----      -----       -----      -----
         General and administrative expenses................           10.3       13.9        10.1       13.5
         Amortization of intangible assets..................            1.6        2.4         1.6        2.4
         Interest income....................................           (0.3)      (0.2)       (0.3)      (0.2)
         Interest expense...................................            0.8        1.2         0.8        1.2
                                                                      -----      -----       -----      -----
              Total other expenses..........................           12.4       17.3        12.2       16.9
         Income before income taxes.........................            3.0        5.7         2.7        5.7
         Provision for income taxes.........................            0.3        0.9         0.3        0.8
                                                                      -----      -----       -----      -----
         Net income.........................................            2.7%       4.8%        2.4%       4.9%
                                                                      =====      =====       =====      =====
</TABLE>

   Three Months Ended June 30, 2000 Compared to Three Months Ended June 30, 1999

     Revenues  for the  quarter  ended June 30,  2000 were  approximately  $13.5
million as compared to  approximately  $10.9  million for the quarter ended June
30,  1999,  an  increase  of  24.6%.  Approximately  41.7%  of the  increase  is
attributable to same market growth in reimbursed costs and Business Service fees
in the  Reproductive  Science  Centers,  offset by the elimination of terminated
Business Services contracts. Approximately 58.3% of the increase is attributable
to new businesses and agreements entered into subsequent to the first quarter of
1999. Same market growth in revenues was  principally  attributable to increases
in patient  volume.  The same market  increase in revenues was  comprised of the
following:  (i) an  approximate  $1.6 million  increase in  reimbursed  costs of
services  associated with the increased patient volume,  offset by a decrease of
$0.8  million  in  the  Company's   Business  Services  fees  derived  from  the
Reproductive Science Centers' net revenue and/or earnings; and (ii) $1.9 million
from pharmaceutical sales.

     Total  costs of  services as a  percentage  of  revenues  were 84.6% in the
second  quarter  of  2000,  compared  to 77.0% in the  second  quarter  of 1999.
Employee  compensation  increased  as a  percentage  of revenue,  due to planned
headcount increases at various  Reproductive  Science Centers.  Direct materials
increased as a percentage  of  revenues,  primarily  due to the cost of products
sold at  IntegraMed  Pharmaceutical  Services.  Other  expenses  decreased  as a
percentage of revenue  partially due to the elimination of reserves required for
the Kansas City operation.

                                       8
<PAGE>

     Contribution was  approximately  $2.1 million in the second quarter of 2000
as  compared  to $2.5  million in the  second  quarter  of 1999,  a decrease  of
approximately 16.8%. This decrease is the result of (i) the reduced contribution
from the hospital based  Reproductive  Science  Center in New Jersey,  which has
exhibited declining revenues due to physician turnover,  (ii) increased expenses
at the Boston based Reproductive Science Center, primarily the result of planned
infrastructure  improvements,  (iii) the termination of the Company's government
contract  in  Washington,  DC,  and  (iv)  the  wind  down  of the  Kansas  City
Reproductive  Science Center operations.  In addition,  the contribution  margin
percentage has been negatively  impacted by pharmaceutical  sales,  which have a
significantly lower margin than the Reproductive Science Centers.

     General and  administrative  expenses  for the second  quarter of 2000 were
approximately  $1.4  million as compared to  approximately  $1.5  million in the
second  quarter of 1999,  a decrease of 8.1%.  The  decrease  was largely due to
decreases in staffing and compensation attributable to the implementation of the
Company's proprietary ARTWorks suite of fertility care information systems. As a
percentage  of  revenues,  general  and  administrative  expenses  decreased  to
approximately  10.3% in the second quarter of 2000 from  approximately  13.9% in
the second quarter of 1999.

     Amortization  of  intangible  assets was $214,000 in the second  quarter of
2000 as compared to $261,000 in the second quarter of 1999, a decrease of 18.0%.
This decrease was attributable to the termination of single physician  practices
during the 1999 calendar year.

     Interest  income for the first  quarter of 2000  increased  to $35,000 from
$18,000  for the  second  quarter  of 1999,  due to a higher  cash  balance  and
financing proceeds from Reproductive Science Center build-outs. Interest expense
for the second quarter of 2000 decreased to $103,000 from $125,000 in the second
quarter of 1999,  due to an decrease in notes  payable to Medical  Providers for
exclusive Business Service rights.

     The  provision  for income  taxes  primarily  related to state  taxes.  The
provision  for income taxes  decreased to $39,000 in the second  quarter of 2000
from  $91,000  in the  second  quarter  of 1999 due to the  decrease  in Network
contribution at existing sites, and additional tax planning considerations.

     Net  income was  $368,000  in the second  quarter  of 2000 as  compared  to
$526,000 in the second  quarter of 1999,  a decrease of 30.0%.  The decrease was
primarily due to (i) decreasing  revenues  related to physician  turnover at the
Company's  hospital  based  Reproductive  Science  Center  in New  Jersey,  (ii)
increased  infrastructure costs at the Boston Reproductive Science Center, (iii)
the termination of the Company's government contract in Washington,  DC and (iv)
the wind down of the Kansas City Reproductive Science Center operations.

   Six Months Ended June 30, 2000 Compared to Six Months Ended June 30, 1999

     Revenues  for the six months ended June 30, 2000 were  approximately  $27.1
million as compared to approximately $21.4 million for the six months ended June
30,  1999,  an  increase  of  26.8%.  Approximately  45.3%  of the  increase  is
attributable to same market growth in reimbursed costs and Business Service fees
in the  Reproductive  Science  Centers,  offset by the elimination of terminated
Business Services contracts. Approximately 54.7% of the increase is attributable
to new  businesses  and  agreements  entered into during June 1999.  Same market
growth in revenues was principally  attributable to increases in patient volume.
The same market  increase in revenues  was  comprised of the  following:  (i) an
approximate $3.4 million  increase in reimbursed costs of services,  offset by a
decrease of $1.5 million in the  Company's  Business  Services fees derived from
the Reproductive  Science  Centers' net revenue and/or  earnings;  and (ii) $3.8
million from pharmaceutical sales.

                                       9

<PAGE>


     Total costs of services as a percentage  of revenues  were 85.1% during the
first six months of 2000,  compared to 77.4% in the same period of 1999.  Direct
materials  increased as a percentage  of revenues,  primarily due to the cost of
products sold at IntegraMed Pharmaceutical Services. This increase was partially
offset by a reduction in expenses  associated  with the donor egg program in the
Company's hospital based Reproductive Science Center.

     Contribution was approximately  $4.0 million during the first six months of
2000 as compared to $4.8  million  during the same period of 1999, a decrease of
approximately 16.2%. This decrease is the result of (i) the reduced contribution
from the hospital based  Reproductive  Science  Center in New Jersey,  which has
exhibited a decline in revenues due to the physician  turnover,  (ii)  increased
expenses at the Boston based Reproductive  Science Center,  primarily the result
of planned infrastructure improvements, and (iii) the wind down of operations in
the  Company's  Kansas  City  Reproductive  Science  Center.  In  addition,  the
contribution  margin  percentage  has  been  negatively  impacted  by  a  higher
proportion  of revenue from  pharmaceutical  sales,  which have a  significantly
lower margin than the Reproductive Science Centers.

     General and  administrative  expenses for the first six months of 2000 were
approximately  $2.7  million as compared to  approximately  $2.9 million for the
first  half of 1999,  a  decrease  of 5.3%.  The  decrease  was  largely  due to
decreases in staffing and compensation attributable to the implementation of the
Company's proprietary ARTWorks suite of fertility care information systems. As a
percentage  of  revenues,  general  and  administrative  expenses  decreased  to
approximately  10.1% for the first six months of 2000 from  approximately  13.5%
during the first half of 1999.

     Amortization  of intangible  assets was $434,000 for the first half of 2000
as  compared to  $505,000  during the same period of 1999,  a decrease of 14.1%.
This decrease was attributable to the termination of single physician  practices
during the 1999 calendar year.

     Interest  income for the first six months of 2000 increased to $85,000 from
$41,000 for same  period of 1999,  due to a higher  cash  balance and  financing
proceeds from Reproductive  Science Center build-outs.  Interest expense for the
first six months of 2000  decreased to $219,000  from  $260,000  during the same
period of 1999,  due to an decrease in notes  payable to Medical  Providers  for
exclusive  Business Service rights,  and a partial payment on a credit line from
the Company's financing institution.

     The  provision  for  income  taxes is  primarily  related  to state  taxes.
Comparing  the first six  months  of 2000 to the first six  months of 1999,  the
provision  for income  taxes  decreased  from  $171,000  to  $84,000  due to the
decrease in Network  contribution at existing sites, and additional tax planning
considerations.

     Net income was  $658,000  for the first six months of 2000 as  compared  to
$1.0 million for the first six months of 1999, a decrease of 37.0%. The decrease
was primarily due to (i) decreasing  revenues  related to physician  turnover at
the Company's  hospital based  Reproductive  Science Center in New Jersey,  (ii)
increased  infrastructure  costs at the Boston Reproductive  Science Center, and
(iii) the wind down of the Kansas City Reproductive Science Center operations.


Liquidity and Capital Resources

     Historically,  the Company has financed its  operations  primarily  through
sales of equity securities.  More recently, the Company has commenced using bank
financing for working capital and acquisition purposes.  The Company anticipates
that its acquisition and product  development  strategy will continue to require
substantial  capital  investment.  Capital  is  needed  not only for  additional
acquisitions, but also for the effective integration, operation and expansion of
the Company's existing  Reproductive  Science Centers as well as the development
of new products and services.

     At June 30, 2000,  the Company had working  capital of  approximately  $4.5
million,  approximately  $3.5  million  of  which  consisted  of cash  and  cash
equivalents,  compared  to working  capital  of  approximately  $5.7  million at
December 31,  1999,  approximately  $3.7 million of which  consisted of cash and
cash  equivalents.  The net  decrease  in working  capital at June 30,  2000 was
principally due to (i) the repurchase of 564,750 shares of the Company's  Common
Stock for an aggregate purchase price of $1.8 million,  (ii) the payoff of notes
payable to Medical  Providers for exclusive  Business Service rights,  and (iii)
scheduled debt repayments on existing credit lines with the Company's  financial
institution.

                                       10
<PAGE>


     The Company anticipates that its contract with the hospital-based Institute
of  Reproductive  Medicine and Science of Saint  Barnabas  Medical Center in New
Jersey  will  expire  at the end of 2001  and will  not be  renewed.  Annualized
revenues and contribution from that contract approximate $2.85 million and $1.47
million, respectively.

     The Company is coming under increased  pressure from the Medical  Practices
associated with its Reproductive  Science Centers to reduce the Business Service
fees  associated  with the  Reproductive  Science  Centers' net revenues  and/or
earnings.  The Company is unable to determine at this time the impact and amount
of such possible reductions in income.

     The  Company has been unable to add any new  Reproductive  Science  Centers
within the last two years due to  changing  market  conditions.  The  Company is
adjusting its service and product offerings to what it believes will be accepted
in the market.  There is no assurance that the Company's new service and product
offerings will be successful.

       The  Company  expects  its cash flows  from  operating  activities  to be
sufficient  to fund  its  needs  for  asset  acquisition,  product  and  service
development,  debt repayments and Common Stock  repurchase  program for the next
year.

Forward Looking Statements

     This Form 10-Q and discussions and/or announcements made by or on behalf of
the Company, contain certain forward-looking  statements regarding events and/or
anticipated  results  within the  meaning of the safe harbor  provisions  of the
Private  Securities  Litigation  Reform  Act of 1995,  the  attainment  of which
involve  various  risks and  uncertainties.  Forward-looking  statements  may be
identified by the use of forward-looking terminology such as, may, will, expect,
believe, estimate,  anticipate,  continue, or similar terms, variations of those
terms or the negative of those terms.  The Company's  actual  results may differ
materially from those described in these  forward-looking  statements due to the
following factors:  the Company's ability to acquire additional business service
agreements,  including the  Company's  ability to raise  additional  debt and/or
equity  capital to  finance  future  growth,  the loss of  significant  business
service agreement(s),  the profitability or lack thereof at Reproductive Science
Centers  serviced by the Company,  increases in overhead due to  expansion,  the
exclusion of infertility  and ART services from insurance  coverage,  government
laws and regulations regarding health care, changes in managed care contracting,
the timely development of and acceptance of new infertility,  ART and/or genetic
technologies and techniques.

Item 3.  Quantitative and Qualitative Disclosures About Market Risk

     Not applicable.

                                       11

<PAGE>


Part II -         OTHER INFORMATION

     Item 1.      Legal Proceedings.
                     None;  no  material  developments  in  previously  reported
                     matters.

     Item 2.      Changes in Securities.
                     None.

     Item 3.      Defaults Upon Senior Securities.
                     None.

     Item 4.      Submission of Matters to Vote of Security Holders.
                     At an annual  shareholders'  meeting  held on May 23, 2000,
                  the  following  matters  were  approved:  1) Election of eight
                  directors;  and 2) approval and  ratification of the Company's
                  2000   Long-Term   Compensation   Plan.  The  following  is  a
                  tabulation  of the  shareholder  votes  from the May 23,  2000
                  Annual Meeting of Shareholders:

                                                                   Withhold
                   Proposal 1 - Directors             For         Authority
                   ----------------------             ---         ---------
                   Gerardo Canet                  3,530,513        192,077
                   M. Fazle Husain                3,530,513        192,077
                   Michael J. Levy, M.D.          3,530,513        192,077
                   Sarason D. Liebler             3,530,513        192,077
                   Aaron S. Lifchez, M.D.         3,530,513        192,077
                   Patricia M. McShane, M.D.      3,530,513        192,077
                   Lawrence Stuesser              3,530,513        192,077
                   Elizabeth E. Tallett           3,530,513        192,077
<TABLE>

<CAPTION>
                   Proposal 2 - 2000 Long-Term                     Withhold                          Broker
                   Compensation Plan                  For          Authority        Abstentions     Non-Votes
                   ------------------                 ---          ---------        -----------     ---------
<S>                                               <C>              <C>                 <C>          <C>
                                                  2,063,367        221,222             4,175        1,433,821
</TABLE>

     Item 5.      Other Information.
                     None.

     Item 6.      Exhibits and Reports on Form 8-K.
                     (a)    Exhibits
                            See Index to Exhibits on page 14.

                     (b)    Reports on Form 8-K
                            None.

                                       12
<PAGE>







                                   SIGNATURES


         Pursuant to the  requirements  of the Securities  Exchange Act of 1934,
the  Registrant  has duly  caused  this report to be signed on its behalf by the
undersigned thereunto duly authorized.


                                               INTEGRAMED AMERICA, INC.
                                               (Registrant)




Date:    August 14, 2000              By:      /s/John W. Hlywak, Jr.
                                               ----------------------
                                               Senior Vice President and
                                               Chief Financial Officer
                                               (Duly Authorized Officer and
                                               Principal Financial and
                                               Accounting Officer)

                                       13
<PAGE>



                                INDEX TO EXHIBITS

Exhibit
Number                               Exhibit

10.61(c)  --   Amendment  No.  3  to  Management  Agreement  between  IntegraMed
               America,  Inc.  and Bay Area  Fertility  and  Gynecology  Medical
               Group, Inc. dated April 1, 2000

10.95(b)  --   Amendment  No.  7  to  Management  Agreement  between  IntegraMed
               America, Inc. and Fertility Centers of Illinois, P.C. dated April
               1, 2000.

10.105(d) --   Amendment  No.  4  to  Management  Agreement  between  IntegraMed
               America,  Inc. and Shady Grove Reproductive  Science Center, P.C.
               dated April 1, 2000.

10.117    --   Form of  Indemnification  Agreement  dated  June 1, 2000  between
               IntegraMed America, Inc. and M. Fazle Husain, Michael Levy, M.D.,
               Aaron Lifchez, M.D., Sarason Liebler,  Larry Stuesser,  Elizabeth
               E. Tallett,  Gerardo Canet,  Peter  Cucchiara,  Jay Higham,  John
               Hlywak, Jr., Claude E. White, and Donald S. Wood, Ph.D.

27        --   Financial Data Schedule

                                       14